RxDoctor Payments Data

Areeg El-Gharbawy

Clinical Genetics (M.D.) · Durham, NCNPI 1629231451

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,696 of the $4,948 with a category attached, or 74.7%. Amicus Therapeutics, Inc. accounts for 74.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $3,736 and has fallen 69.5% since, to $1,138 in 2023.

$4,948in general payments, 2019–2025

Across 11 payments — averaging $449.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amicus Therapeutics, Inc.$4K
  • Modernatx, Inc.$1K
  • Sanofi$58
  • Amgen$57
  • Sanofi-aventis U.S. LLC$56
$1,269,953in research payments, 2019–2025

Across 129 payments — averaging $9844.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ultragenyx Pharmaceutical Inc.$871K
  • Modernatx, Inc.$399K

What the payments were for

  • Consulting fees$3,69675%
  • Travel & lodging$80516%
  • Food & beverage$4479%

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few clinical genetics (m.d.) providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Other clinical genetics (m.d.) in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →